Conclusions

Based on the results of this observational study describing experiences with inclisiran from a single center, we assume a comparable effect of administration as in clinical studies with nearly 100% adherence and without significant adverse effects. The overall management of patients receiving inclisiran therapy is straightforward, requiring no complex administration; the costs for ordering the therapy arise in the outpatient setting only after reimbursement by the health insurance company (with an invoice maturity of 60–75 days). Due to favorable indication criteria, the therapy is generally accessible, and administration is not limited to specialized centers. The therapy guarantees the achievement of target LDL-C values in over 63.4 % of patients, for whom we would not have reached target LDL-C values without this therapy. We anticipate that the availability and potential widespread implementation of this therapy in patients with very high CV risk could lead to better management of hyperlipidemia and significant reductions in CV morbidity and mortality. Since this is a pilot observational study with limitations regarding sample size, we expect the contribution of additional larger studies that would examine the more comprehensive effects of hypolipidemic therapy with inclisiran, involving multiple centers and a broader patient group.

REFERENCES

1. Vardas P, Townsend N, Torbica A, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716-799.
2. Štatistický úrad SR. Najčastejšie príčiny úmrtia obyvateľov SR [Internet]. 2023 [cited 25-01-02]. Available from: https://statdat.statistics.sk/.
3. Český statistický úřad. Smrt v datech [Internet]. 2023 [cited 25-01-02]. Available from: https://statistikaamy.csu.gov.cz/.
4. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
5. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308-1321.
6. Khvorova A. Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. N Engl J Med. 2017;376(1):4-7.
7. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530.
8. Alonso R, Arroyo-Olivares R, Muñiz-Grijalvo O, et al. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study. Eur J Prev Cardiol. 2023;30(4):320-328.
9. A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). Available from: https://clinicaltrials.gov/ct2/show/NCT03705234. Accessed: November 16, 2024.
10. Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067-1075.
11. Ray KK, Troquay RP, Visseren FI, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109-119.
12. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530.
13. Katsiki N, Vrablik M, Banach M, et al. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel). 2023;16(4):577.
14. Padam P, Barton L, Wilson S, et al. Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart. 2022;9(2):e002184.
15. Basile C, Gargiulo P, Merlini PA, et al. Efficacy and safety of inclisiran in real-world practice: insights from the Cholinet registry. Eur Heart J. 2023;44(Suppl 2):ehad655-2812.
16. Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024; 120(12):1400-1410.
17. Makhmudova U, Schatz U, Perakakis N, et al. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. 2023;112(11):1639-1649.
18. Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17(6):818-827.
19. Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25(5):387-393.
20. Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010;51(6):1486-1495.
21. Bao X, Liang Y, Chang H, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13.
22. Patnaik S, Pollevick ME, Lara-Breitinger KM, et al. Inter-individual variability in lipid response: a narrative review. Am J Med. 2022;135(12):1427-1433.e7.
23. Ray KK, Bruckert E, Peronne-Filardi P, et al. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study. Atherosclerosis. 2023;366:14-21.
24. Vonbank A, Drexel H, Agewall S, et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. Eur Heart J Cardiovasc Pharmacother. 2018;4(4):230-236.
25. Arnold N, Koenig W. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. Curr Cardiol Rep. 2022;24(11):1657-1667.
26. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722.
27. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107.
28. Bittner VA, Schwartz GG, Bhatt DL, et al. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. J Clin Lipidol. 2024;18(4):e548-e561.
29. Ying Q, Chan DC, Watts GF. New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects. Front Physiol. 2021;12:603910.
30. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004; 116(Suppl 6A):S9-S16.
31. Landmesser U, Conde LG, Wright RS, et al. Effect of inclisiran on haematological and immunological biomarkers: a pooled analysis of ORION-9, -10, and -11 trial data. Atherosclerosis. 2021;331:E37.